JPMorgan Chase & Co. reissued their overweight rating on shares of Phoenix Group (LON:PHNX – Get Rating) in a report released on Tuesday, MarketBeat.com reports.
A number of other equities analysts have also recently weighed in on the stock. Berenberg Bank upped their price objective on shares of Phoenix Group from GBX 815 ($9.80) to GBX 820 ($9.86) and gave the company a buy rating in a research report on Monday, January 30th. Barclays reduced their price target on shares of Phoenix Group from GBX 790 ($9.50) to GBX 765 ($9.20) and set an overweight rating on the stock in a research report on Tuesday, February 14th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a hold rating and set a GBX 680 ($8.18) price target on shares of Phoenix Group in a research report on Wednesday, December 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of GBX 725 ($8.72).
Phoenix Group Stock Performance
LON:PHNX opened at GBX 627.60 ($7.55) on Tuesday. The company has a debt-to-equity ratio of 73.43, a current ratio of 0.27 and a quick ratio of 0.12. The firm has a 50-day moving average of GBX 628.72 and a two-hundred day moving average of GBX 597.27. The stock has a market cap of £6.28 billion, a P/E ratio of -602.67, a PEG ratio of 1.95 and a beta of 0.78. Phoenix Group has a 1-year low of GBX 501 ($6.02) and a 1-year high of GBX 690.40 ($8.30).
Phoenix Group Company Profile
Phoenix Group Holdings plc operates in the long-term savings and retirement business in Europe. The company operates through four segments: UK Heritage, UK Open, Europe, and Management Services. It provides a range of pensions and savings products to support people across various stages of the savings life cycle.
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Phoenix Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Group and related companies with MarketBeat.com's FREE daily email newsletter.